Subcutaneous bortezomib in newly diagnosed multiple myeloma patients non-transplant eligible: Retrospective evaluation

Bortezomib-melphalan-prednisone combination is one of the standards of care for non-transplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly/4 cycles then weekly/5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of subcutaneous bortezomib-based combinations in non-transplant eligible patients with newly diagnosed myeloma in a real-world setting.

Source: Seminars in Hematology - October 13, 2017 Category: Hematology Authors: Felipe de Arriba de la Fuente, Maria Soledad Dur án, Miguel Ángel Álvarez, Isabel López Sanromán, Ana Maria Dios, Rafael Ríos Tamayo, Ricarda García, Marta Sonia González, Elena Prieto, Abelardo Bárez, Fernando Escalante, Aurelia Tejedor, Mónica Source Type: research